Back to top
more

Impax Laboratories, Inc. (IPXL)

(Real Time Quote from BATS)

$18.30 USD

18.30
3,041,017

0.00 (0.00%)

Updated May 4, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

New Strong Sell Stocks for April 26th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?

    Impax Laboratories (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y

      Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.

        Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?

        Impax Laboratories (IPXL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

          Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

          Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

            Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

            Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

              Impax Generic Division Progresses Well Amid Pricing Pressure

              Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.

                Impax Laboratories, Inc. (IPXL) in Focus: Stock Moves 20.6% Higher

                Impax Laboratories, Inc. (IPXL) was a big mover last session, as the company saw its shares rise nearly 21% on the day.

                  Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y

                  Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.

                    3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings

                    The first half has been pretty strong for companies in the space.

                      Should You Buy Impax Laboratories (IPXL) Ahead of Earnings?

                      Impax Laboratories, Inc. (IPXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                        What's in Store for Catalyst (CPRX) This Earnings Season?

                        With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.

                          What's in Store for BioDelivery (BDSI) This Earnings Season?

                          BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.

                            Arpita Dutt headshot

                            Generic Drug Stocks Take a Hit: Here's Why

                            As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.

                              Mylan (MYL) to Report Q2 Earnings: What's in the Cards?

                              Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.

                                Is Zoetis (ZTS) Poised for a Beat This Earnings Season?

                                Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.

                                  Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?

                                  Horizon Pharma (HZNP) is set to report second-quarter results next week and we expect investor focus on sales of key drugs.

                                    Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?

                                    While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.

                                      Can Prothena (PRTA) Deliver a Beat this Earnings Season?

                                      Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

                                        What's in the Cards for Aerie (AERI) This Earnings Season?

                                        Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.

                                          Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen

                                          Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.

                                            Why Is Impax (IPXL) Down 2.4% Since the Last Earnings Report?

                                            Impax (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

                                              AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

                                                Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                                                Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                                                  Arpita Dutt headshot

                                                  Generic Drugmakers Tumble as Perrigo Discloses DoJ Search

                                                  With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.